Thermo Fisher Scientific Inc. (NYSE:TMO) is listed among the 14 Best Pharma Dividend Stocks to Buy in 2026. Bank of America raised its price target for TMO to $700 from $650, citing a recovery in biopharma spending. Thermo Fisher also acquired data management company Clario for up to $9.4 billion to strengthen its clinical trial research business.

The acquisition of Clario marks Thermo Fisher’s third major acquisition this year, boosting its presence in clinical development. The company operates as a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, and laboratory services. While TMO presents investment potential, some believe certain AI stocks offer greater upside and less downside risk.

For more insights, check out 10 Cash-Rich Stocks to Buy Now and 15 Global Dividend Stocks to Diversify Your Portfolio. No disclosure stated.

Read more at Yahoo Finance: BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View